Patients with MPD and underlying invasive breast carcinoma (IBC) experience significantly worse survival compared to those with IBC alone, driven by higher lymph node involvement, reduced hormone receptor expression, and elevated HER2 positivity. The gene discussed is NR4A1; the disease is inflammatory breast carcinoma.